Abstract
Isolated limb perfusion (ILP) has now been practised for years [1], but many fundamental issues remain to resolved. This paper summarises three studies we have performed.
This work was funded by the Cancer Research Campaign. R.N.S. is in receipt of a travel grant from Lanarkshire Health Board.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Creech OJ, Krementz ET, Ryan RF, Winblad JN (1958) Chemotherapy of cancer: regional perfusion utilising an extracorporeal circuit. Ann Surg 148:616–632
Chang SY, Alberts DS, Farquar D, Melnick LR, Walson PD, Salmon SE (1978) Hydrolysis and protein binding of melphalan. J Pharm Sci 67:682–684
Hafstrom L, Hugander A, Jonsson P-E, Westling H, Ehrsson H (1984) Blood leakage and melphalan leakage from the perfusion circuit during regional hyperthermic perfusion for malignant melanoma. Cancer Treat Rep 68:867–872
Briele HA, Djuric M, Jung DT, Mortell T, Patel MK, Das Gupta TK (1985) Pharmacokinetics of melphalan in clinical isolation perfusion of the extremities. Cancer Res 45:1885–1889
Minor DR, Allen RE, Alberts D, Peng Y-M, Tardelli G, Hutchinson J (1985) A clinical and pharmacokinetic study of isolated limb perfusion with heat and melphalan for melanoma. Cancer 55:2638–2644
Scott RN, Blackie R, Kerr DJ, Hughes J, Burnside G, MacKie RM, Kaye SB, McKay AJ (1987) Melphalan pharmacokinetics in isolated limb perfusion (ILP) for melanoma (abstract). ICRCT 87, Ulm, p G31
Benckhuijsen C, Kroom BBR, van Geel AN, Wieberdink J (1988) Regional perfusion treatment with melphalan for melanoma in a limb: an evaluation of drug kinetics. Eur J Surg Oncol 14:157–163
Osterheld HKO, Musch E, von Unruh GE, Loos U, Rauschecker H, Muhlenbruch BJ (1988) A sensitive high-performance liquid chromatographic assay for melphalan and its hydrolysis products in blood and plasma. Cancer Chemother Pharmacol 21:156–162
Kroon BBR (1988) Regional isolation perfusion in melanoma of the limbs; accomplishments, unsolved problems, future. Eur J Surg Oncol 14:101–110
Furner RL, Brown RK (1980) L-Phenylalanine mustard (L-PAM): the first 25 years. Cancer Treat Rep 64:559–574
Scott RN, Wheldon TE, Kaye SB, MacKie RM, McKay AJ (1987) Multicellular tumour spheroids (MTS) as a model for thermochemotherapy with melphalan (abstract). ICRCT 87, Ulm, pA19
Yuhas JM, Li AP, Martinez AO, Ladman AJ (1977) A simplified method for production and growth of multicellular tumour spheroids. Cancer Res 37:3639–3643
Twentyman PR (1980) Response to chemotherapy of EMT6 spheroids as measured by growth delay and cell survival. Br J Cancer 42:297–304
Parsons PG, Carter FB, Morrison L, Regius Mary Jr (1981) Mechanism of melphalan resistance developed in vitro in human melanoma cells. Cancer Res 41:1524–1534
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1990 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Scott, R.N. et al. (1990). Melphalan in Isolated Limb Perfusion for Malignant Melanoma, Bolus or Divided Dose, Tissue Levels, the pH Effect. In: Jakesz, R., Rainer, H. (eds) Progress in Regional Cancer Therapy. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-74818-9_33
Download citation
DOI: https://doi.org/10.1007/978-3-642-74818-9_33
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-74820-2
Online ISBN: 978-3-642-74818-9
eBook Packages: Springer Book Archive